Information  X 
Enter a valid email address

Vectura Group plc (VEC)

  Print      Mail a friend

Thursday 10 October, 2019

Vectura Group plc

Results of General Meeting

RNS Number : 5145P
Vectura Group plc
10 October 2019


Results of General Meeting

Results of the General Meeting held on 10 October 2019 at the offices of Clifford Chance LLP, 4 Coleman Street, London EC2R 5JJ.


Chippenham, UK - 10 October 2019: Vectura Group plc (LSE: VEC) ("Vectura" or "the Company") announces that all resolutions proposed to shareholders at its General Meeting (GM) held today were duly passed on a poll, the results of which are set out below:



No. of votes for & discretionary


No. of votes against


No. of total votes cast


No. of votes withheld

To declare a Special Dividend of 6 pence per ordinary share in the capital of the Company
































To approve the share consolidation as set out in the Circular


























To authorise market purchases of the Company's own shares*



























* Passed as a special resolution.


Votes 'withheld' have not been included in the calculation of whether a resolution is carried.


A copy of the resolutions as well as the above results will shortly be available on the Company's website at


A copy of the resolutions will be submitted to the National Storage Mechanism and in due course will be available to view at using Vectura Group PLC's code 'VEC'.


As at the close of business on 10 October 2019, the issued share capital was 666,581,058 ordinary shares of £0.00025 each, carrying one vote each. At 10 October 2019 the Company did not hold any shares in treasury. Therefore, the total number of voting rights in the Company as at 10 October 2019 was 666,581,058.


- Ends-



For more information, please contact:

Vectura Group plc

Elizabeth Knowles - VP Investor Relations                          +44 (0)7767 160 565

David Ginivan - VP Corporate Communications                 +44 (0)7471 352 720


Consilium Strategic Communications                                 +44 (0)20 3709 5700

Mary-Jane Elliott / Sue Stuart / David Daley


About Vectura

Vectura is a provider of innovative inhaled drug delivery solutions that enable partners to bring their medicines to patients.  With differentiated proprietary technology and pharmaceutical development expertise, Vectura is one of the few companies globally with the device, formulation and development capabilities to deliver a broad range of complex inhaled therapies. 

Vectura has ten key inhaled and eleven non-inhaled products marketed by partners with global royalty streams, and a diverse partnered portfolio of drugs in clinical development. Our partners include Hikma, Novartis, Sandoz (a division of Novartis AG), Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin KingYork.

For further information, please visit Vectura's website at

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

a d v e r t i s e m e n t